How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?

Kim, B.J.; Lee, K.T.; Moon, Tae Gun; Kang, Pung; Lee, J.K.; Kim, J.J.; Rhee, Jong Chul

doi:10.1016/j.dld.2008.12.094

Cited by 42 publications

(23 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our data suggested that 1.8% of carcinomas were diagnosed in the follow-up cohort, which is similar to the results of a previous study [ 8 ]. All were male.…”

Section: Discussionsupporting

confidence: 93%

See 1 more Smart Citation

Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China

Tong

Song

Zhu

2013

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…Our data suggested that 1.8% of carcinomas were diagnosed in the follow-up cohort, which is similar to the results of a previous study [ 8 ]. All were male.…”

Section: Discussionsupporting

confidence: 93%

“…A previous study revealed that 1.3% of 62,976 individuals had elevated CA19-9 concentrations in Korea [ 8 ]. However, the appropriate medical advice for those asymptomatic individuals remains unknown.…”

Section: Introductionmentioning

confidence: 97%

Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China

Tong

Song

Zhu

2013

Clinical Chemistry and Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…This situation indicates an urgent need for improved diagnosis aiming to detect pancreatic cancer at an early resectable stage which is the best hope for cure. Serum-based diagnosis is highly desirable; the best available marker in current use, CA19-9 has a sensitivity of approximately 80% and is not adequate for screening purposes particularly for the diagnosis of localized, resectable pancreatic cancers (Steinberg, 1990;Kim et al, 2009;Duffy et al, 2010;Ni et al, 2005). Enormous effort has been put into biomarker discovery in plasma or serum of cancer patients.…”

Section: Introductionmentioning

confidence: 98%

Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells

et al. 2011

View full text Add to dashboard Cite

“…Therefore, it is necessary to find tumor biomarkers for early diagnosis or tumor stage prediction. Currently the best marker available is carbohydrate antigen 19-9, which has a sensitivity of approximately 80% and thus is not adequate for screening purposes, particularly for the diagnosis of localized, resectable pancreatic cancers [4,5].…”

mentioning

confidence: 99%

Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters

Zhang

Zhou

et al. 2012

Sci. China Life Sci.

View full text Add to dashboard Cite

Catechol-O-methyl transferase (COMT) is an enzyme involved in estrogen metabolism. Proteomic and immunoproteomic screens suggested COMT might be an immunogenic membrane antigen in human pancreatic cancer. The aim of this study was to investigate the dynamic expression of COMT in pancreatic ductal adenocarcinoma (PDAC) and noncancerous pancreatic tissue, and to determine the relationship between COMT expression and clinicopathologic parameters. COMT expression was analyzed by reverse transcription-polymerase chain reaction (RT-PCR) and western blot in five pancreatic cell lines and five pairs of PDAC and noncancerous pancreatic tissue. Immunohistochemistry was used to evaluate COMT expression in tissue microarrays and 20 cases of paraffin-embedded clinical specimens. The results indicated that COMT expression was detected in AsPC-1, BxPC-3, MIA PaCa-2, Capan-1 and SW1990 pancreatic cell lines, and in five pairs of PDAC and noncancerous pancreatic tissue, at the mRNA and protein levels. Immunohistochemistry analysis revealed that COMT expression was significantly higher in PDAC than in nonmalignant pancreatic tissue. High expression of COMT significantly correlated to early T stages. Therefore, we conclude that COMT might serve as a potential biomarker for applied clinical pathology in PDAC. COMT, pancreatic cancer, immunohistochemistry, biomarker Citation:Wu W M, Zhang J, Zhou L, et al. Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters. Sci China Life Sci, 2012, 55: 747 -752,

show abstract

How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?

Cited by 42 publications

References 24 publications

Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China

Study of an elevated carbohydrate antigen 19-9 concentration in a large health check-up cohort in China

Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells

Increased COMT expression in pancreatic cancer and correlation with clinicopathologic parameters

Contact Info

Product

Resources

About